Bone Marrow Langerhans Cell Histiocytosis in Association with Kasabach-Merritt Syndrome: The Difficulty of a Differential Diagnosis by Serra, JT et al.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Case Report
Case Rep Oncol 2020;13:408–413
Bone Marrow Langerhans Cell Histiocytosis in 
Association with Kasabach-Merritt Syndrome: 
The Difficulty of a Differential Diagnosis
Joao Tiago Serra    Raquel Silva    Fernando Aldomiro    Fernanda 
Paixao Duarte 
Department of Internal Medicine II, Professor Doutor Fernando Fonseca Hospital,  
Amadora, Portugal
Keywords
Langerhans cell histiocytosis · Kasabach-Merritt syndrome · Idiopathic thrombocytopenic 
purpura · Intravascular disseminated coagulopathy · Tuberculosis
Abstract
Langerhans cell histiocytosis is a rare haematological disorder with variable clinical findings 
and a high mortality rate. On the other hand, Kasabach-Merritt syndrome is of rare onset at 
adult age, requiring the simultaneous presentation of vascular lesion, thrombocytopenia, and 
consumptive coagulopathy. We present the first reported case of both diseases in a single 
patient and highlight the difficulties of diagnostic. A 69-year-old woman with immune throm-
bocytopenic purpura underwent surgery for the removal of giant skin haemangiomas. During 
post-operative care, intravascular disseminated coagulopathy developed. After weeks of cor-
ticosteroids and immunosuppressive therapy with no clinical improvement, pulmonary tuber-
culosis was diagnosed and appropriate treatment initiated. Despite all the efforts, the pa-
tient’s clinical condition kept worsening and she eventually died. An autopsy revealed bone 
marrow Langerhans cell histiocytosis. In this case, the patient’s autoimmune background to-
gether with tuberculosis and intravascular disseminated coagulopathy masked the presenta-
tion and made the diagnosis of a rapidly progressive fatal disease very difficult.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Langerhans cell histiocytosis (LCH) is a rare disease of unknown aetiology, characterized 
by a proliferation of lymphocytic cells with specific morphology, ultrastructure, and phenotype 
[1]. Although usually diagnosed in young children, it can occur in adulthood with an estimated 
incidence of 1–2 cases per million, mostly caucasian males [1, 2]. The pathogenesis remains 
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unclear, contributing to the indecision on whether LCH should be considered a hyperplastic 
reactive disorder or a neoplasm. Diagnosis can be misleading, since clinical features vary 
from an asymptomatic solitary lesion to a lethal multisystemic disease. In the latter case, any 
organ can be involved, but bone and skin are more commonly affected [3]. The current 
standard of care for LCH is based on site and disease extension, with a survival rate of less 
than 50% for high-risk patients [2, 4].
Kasabach-Merritt syndrome (KMS) rarely presents in adults, occurring almost exclu-
sively in infants and young children. The diagnosis requires a triad of a vascular lesion, throm-
bocytopenia, and consumptive coagulopathy [5, 6]. KMS pathogenesis is poorly understood, 
although platelet and fibrinogen consumption by intralesional thrombosis are accepted as 
the underlying mechanism [7]. There are currently no guidelines for the management of 
KMS, but the general approach is to control coagulopathy with supportive care and medical 
therapy [5].
We present the first known case of an association between these two rare conditions, 
briefly review the underlying literature, and focus on the clinical manifestations and the diffi-
culties of differential diagnosis.
Case Report
A 69-year-old caucasian woman was admitted to our hospital for the removal of giant 
dorsal haemangiomas. Multiple scattered cutaneous vascular lesions had emerged in recent 
years (Fig. 1) and prompted excision surgery before. There was also a medical background of 
immune thrombocytopenic purpura for more than 30 years, under long-term treatment with 
corticosteroids and immunosuppressants (cyclosporine and azathioprine), and multinodular 
goitre associated with hyperthyroidism. There was no history of smoking and besides the 
haemangiomas, there were no other lung, skin or constitutional symptoms.
At admission, the platelet count was 75,000/μL (reference range [RR] 150–400); however, 
after the procedure, it dropped to 19,000/μL, and there was active bleeding from the surgical 
incisions. Methylprednisolone pulses were administered, and immunosuppressive therapy 
was maintained with the platelet count increasing to 47,000/μL and successful bleeding 
control. Nevertheless, during the following weeks, the patient’s condition kept worsening 
with ascites and bilateral relapsing pleural effusion development. Paracentesis, thoracen-
tesis, and bronchofibroscopies were performed, but although with characteristic exudative 
fluids, no pathological agents or malignant cells were ever identified.
At this point, blood analysis showed Hb 7.6 g/dL (RR 11.5–16.5), white blood count 14.9 
× 109/L (RR 4–11), platelet count 3,000/μL, D-dimers 35,923 μg/L (RR <500), fibrinogen 1.2 
g/dL (RR 1.5–4.0), C-reactive protein 5.97 mg/dL (RR <0.30), FT4 3.02 ng/mL (RR 0.8–1.76) 
and TSH 0.006 mIU/L (0.55–4.78). Blood and urine cultures were positive for Enterococcus 
faecium. A diagnosis of disseminated intravascular coagulopathy (DIC) in a patient with KMS 
and sepsis was made. Immunoglobulin, methylprednisolone, plasma, and cryoprecipitate, 
together with broad-spectrum antibiotics were administered. Platelets stabilized at around 
30,000/μL, but a consumptive state with marked weight loss and clinical worsening kept 
progressing. A full-body CT scan was performed with no evidence of tumours, lymphadenop-
athies, or bone lesions.
After weeks, a Löwenstein-Jensen culture from bronchoalveolar lavage became positive 
for Mycobacterium tuberculosis. Standard antibacillary treatment was initiated; however, due 
to hepatotoxicity, the therapeutic scheme had to be readjusted. More than 4 months after 
admission, the patient was discharged on maintenance antibacillaries, corticosteroids, immu-
nosuppressive therapy, and antithyroid drugs.
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Within 2 months she was readmitted due to an extensive left pleural effusion causing 
dyspnoea and respiratory insufficiency. Blood analysis showed Hb 10.1 g/dL, platelet count 
of 3,000/μL, alkaline phosphatase 196 IU/L (RR 50–136), GGT 308 IU/L (RR 5–55) and 
C-reactive protein 11.10 mg/dL. Although no bone lesions had been identified so far, a bone 
marrow aspirate was performed and showed only a reactive bone marrow without signs of 
pathogens or malignant cells.
Active gastrointestinal bleeding eventually arose with the haemoglobin level dropping to 
4 g/dL. Rescue therapy with rituximab was attempted with a platelet count increase to 
42,000/μL and a D-dimer drop to 2,400 μg/L. Despite all the diagnostic and therapeutic 
efforts the patient died.
A post-mortem examination revealed bone marrow infiltration by large cells with an 
irregular core and large cytoplasm (Fig. 2a, b). Immunohistochemistry was positive for CD1a, 
S100, and CD5, and negative for markers of plasmacytic, B- and T-cell differentiation (Fig. 2c). 
Electron microscopy identified Birbeck granules (Fig. 2d). The cause of death was established 
as LCH.
Fig. 1. Haemangioma on the anterior side of the left arm near the elbow joint.
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Discussion
As far as we know this is the first time KMS and LCH have been simultaneously described. 
In adulthood, KMS usually occurs as a complication of haemangiomas, haemangiomatosis, or 
angiosarcoma, and there are a few literature reports of angioma development after treatment 
with immunosuppressive agents [8, 9]. This might have been the case in our patient, since 
multiple vascular skin lesions arose after years of cyclosporine and azathioprine treatment. 
From another perspective, DIC is a serious and potentially fatal acute complication of KMS, 
which has previously been reported after surgically related procedures [10].
In the autopsy report, LCH turned out to be the established cause of death, although diag-
nosis was only achieved post-mortem. The clinical manifestations of LCH can vary widely 
depending on the age of onset, proliferative rate of Langerhans cells, and the organ or system 
Fig. 2. Post-mortem histological images of the bone marrow. a Hypercellular intertrabecular space. H&E. ×4. 
b Cell population with large eosinophilic cytoplasm and cerebriform nucleus. H&E. ×20. c Positive immuno-
histochemical staining for CD1a marker. CD1a+. ×20. d Electron microscopy showing “tennis-racket” cyto-
plasmic organelles characteristic of Birbeck granules. ×40,000.
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affected [1]. Skin disease may be the primary presentation, but it can be easily misdiagnosed 
due to the many different presentations mimicking common dermatological conditions, and 
so requiring a high level of suspicion for early detection [4]. In this case, giant skin haeman-
giomas related to KMS were the dominant problem, masking other skin lesions that might 
have been present.
Immunosuppression-related conditions such as M. tuberculosis infection, not only led to 
the misinterpretation of eventual clinical and radiological LCH lung affection, but were also 
the main explanation for the marked weight loss and consumptive state which were thought 
to be tuberculosis related.
The clinical suspicion of a malignant disease was always present, even though all exami-
nations carried out including a full-body CT scan had not identified any tumours, bone lesions, 
or lymphadenopathies. Thyroid ultrasound and function abnormalities were related to the 
long-term multinodular goitre and did not show any signs of malignancy.
With the development of DIC and acute gastrointestinal bleeding, rescue therapy with 
rituximab was attempted without success [11]. Despite all the efforts, the patient’s clinical 
condition kept worsening and she eventually died. The post-mortem examination revealed a 
bone marrow and lymphatic system LCH. As stated before, this is an extremely rare condition 
in the adult population, particularly with such an aggressive course [4, 12].
The differential diagnosis of LCH includes reactive histiocyte hyperplasia in systemic 
infections, storage diseases, or haemophagocytic lymphohistiocytosis [13]. DIC, KMS, and 
tuberculosis played a major dissimulating role in this case, since not only skin, lung, and 
consumptive findings were attributed to these conditions, but also prevented other diag-
nostic invasive examinations such as a bone marrow biopsy due to severe anaemia and 
thrombocytopenia.
Findings suggest that LCH cells are more likely to arise from dysregulated differentiation 
or recruitment of bone marrow-derived precursor cells rather than from transformed or acti-
vated epidermal Langerhans cells [2,3]. In our case, the continuous state of inflammation 
related to severe infection, combined with a medical background of autoimmunity, might 
have been the cornerstone for LCH development.
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